

## **Trends in Efficacy, Safety, and Tolerability of Approved Multiple Sclerosis Disease Modifying Treatments**

Kyle Valke, BS<sup>1</sup>, Kangho Suh, PharmD, PhD<sup>1</sup>

<sup>1</sup>School of Pharmacy, University of Pittsburgh, Pittsburgh, PA

### **Corresponding Author:**

**Kangho Suh, PharmD, PhD**

**Assistant Professor**

**School of Pharmacy**

**University of Pittsburgh**

**Pittsburgh, PA 15206**

[kas551@pitt.edu](mailto:kas551@pitt.edu)

**Telephone: 412-383-3579**

**Credit Author Statement:** **Kyle Valke:** Conceptualization, Methodology, Formal analysis, Investigation, Writing - Original Draft, Visualization **Kangho Suh:** Conceptualization, Methodology, Formal analysis, Writing - Review & Editing, Visualization, Supervision

**Conflict of Interests:** The authors declare no relevant conflicts of interest or financial relationships.

**Funding Support:** This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Key Words:** Multiple sclerosis, relapsing-remitting multiple sclerosis, disease-modifying therapy, treatment, trends, safety, efficacy, tolerability, review

1 **Abstract**

2

3 **Background:** Disease-modifying therapies (DMTs) have become the mainstay of treatment for  
4 relapsing forms of multiple sclerosis (MS), reducing relapse rates and slowing disease  
5 progression.

6 **Objectives:** To determine whether or not available MS DMTs have demonstrated an increase in  
7 safety, efficacy, and tolerability over time.

8 **Methods:** Results from pivotal phase III trials of approved MS DMTs were used to create a  
9 dataset of relevant outcomes. Common endpoints analyzed include annualized relapse rates  
10 (ARR), rates of serious adverse events (SAE), and rates of discontinuation due to adverse  
11 events. Trial comparator, active or placebo, was also documented. Descriptive statistics and  
12 Fisher exact tests were performed on outcomes stratified by recency of pivotal trials.

13 **Results:** On visual inspection, there was a trend of decrease in ARR. A significant relationship  
14 was seen between recent approvals and trial design with an active comparator ( $p=0.004$ ), as  
15 well as between recent approvals and ARR ( $p=0.020$ ). No significance was found between  
16 recent approvals and SAE ( $p=0.138$ ), formulation and discontinuation ( $p=0.559$ ), or recent  
17 approvals and formulation ( $p=0.352$ ).

18 **Conclusion:** DMTs for relapsing forms of MS increased in efficacy over time. Oral therapies  
19 offered similar tolerability to other routes of administration. Further research is warranted to  
20 identify if these clinical trial findings translate to real world evidence.

21

22 **What was already known:**

- 23 • The number of FDA approved disease-modifying therapies for multiple sclerosis has been  
24 steadily increasing. Available routes of administration include injectable, oral, and infusions.  
25 • These medications are proven to be effective in reducing MS relapse rates and slowing  
26 overall disease progression, with varying degrees of safety and tolerability.  
27 • The comparative efficacy of these therapies varies, with certain medications often deemed  
28 high efficacy.

29

30 **What this study adds:**

- 31 • We used published phase III trial results for each medication to provide a direct comparison  
32 between each medication's efficacy, safety, and tolerability at time of approval.  
33 • Our analysis demonstrates a trend in increasing efficacy of available therapies along with  
34 the use of active comparators for controls in disease modifying treatments for multiple  
35 sclerosis.

36

1 **Background:**

2 Multiple sclerosis is a chronic autoimmune central nervous system (CNS) disorder  
3 characterized by neuronal demyelination. Prevalence of the disease varies by region, seen  
4 significantly more commonly in North America and Europe.<sup>1</sup> Disease course varies by individual,  
5 often broken down into four subtypes: the majority of patients present with a relapsing remitting  
6 course (RRMS) at disease onset, characterized by acute symptomatic exacerbations with a full  
7 or nearly complete return to function afterwards.<sup>2</sup> The most widely used diagnostic criteria for  
8 the disease is the McDonald criteria<sup>3</sup> which combines clinical presentation and history, lesions  
9 found on MRI results, and most recently the presence of CSF-specific oligoclonal bands.  
10 Clinical presentation of the disease is complex, with a wide range of potentially debilitating  
11 symptoms manifesting particularly during acute relapses, requiring a multifaceted approach to  
12 treatment.

13 The mainstay of multiple sclerosis therapy has become disease-modifying therapies  
14 (DMTs) since their emergence in the 90s. These therapies exert immunomodulatory effects and  
15 have demonstrated reductions in the risk of relapses and delaying disease progression.<sup>4</sup>  
16 Approved indications vary by drug however every therapy currently available is approved for  
17 treatment of relapsing-remitting multiple sclerosis. DMTs also vary by route of administration:  
18 injection, oral, or infusion. Newer therapies, particularly monoclonal antibodies which exert more  
19 direct immunomodulatory effects, are generally thought to be the higher efficacy approach to  
20 treatment.<sup>5</sup>

21 **Objective:**

22 The primary objective of this study was to summarize trends in reported efficacy and safety data  
23 for every currently approved DMT, examining whether or not newer agents have demonstrated  
24 equal or greater efficacy and improved safety and tolerability outcomes.

25 **Methods:**

26 PubMed was utilized to collect pivotal phase III trials for all currently FDA approved  
27 DMTs, with trials dating between 1993 through 2022.<sup>6-29</sup> Generic equivalents, novel formulations  
28 of existing medications, and monomethyl fumarate, an active metabolite of dimethyl fumarate  
29 approved based on bioavailability data, were excluded. Safety and efficacy data common  
30 amongst each trial was pulled to create a dataset. Therapies were also categorized based on  
31 route of administration: injectable, oral, or infusion. The primary efficacy endpoint that was  
32 identified and collected from every trial was annualized relapse rate (ARR). Other endpoints  
33 included in the dataset when available were percentages of patients with serious adverse  
34 events as a measure of safety and percentages of patients with adverse events leading to  
35 discontinuation as a measure of tolerability. Trial comparator, active or placebo, was also  
36 collected.

37 ARR was grouped by route of administration and plotted against time to visualize  
38 potential trends. Based on our objective to assess efficacy and safety in recently approved  
39 DMTs compared to older DMTs, we chose *a priori* to run several Fisher's exact tests for recently  
40 approved DMTs in the past 10 years (1993-2012 or 2013-2022) by 1) pivotal trial-reported ARR  
41 (<0.2 or >0.2), 2) annual serious adverse effect (SAE) probability (< 5% or ≥5%), 3) formulation

1 (oral vs injection/infusion), and 4) trial comparator, active or placebo. Additionally, we assessed  
2 whether there was a relationship between tolerability (i.e., annual discontinuation probability  
3 <5% vs ≥5% due to adverse event) and formulation. Level of significance was set at  $p = 0.05$  for  
4 all tests. ARR was deemed the primary measure of overall efficacy as it was reported in all trials  
5 gathered and the primary efficacy endpoint in the vast majority. A cutoff of 0.2 was chosen  
6 based on the mean and median of reported ARRs since a point of clinical relevance was  
7 unclear. Annual probability of SAE was used as the primary measure of safety. Annual  
8 probabilities of SAE and discontinuation due to AE were calculated from respective percentages  
9 of patients from each trial. Due to limitations in available data, safety and tolerability outcomes  
10 were assessed over the last 12 years of the dataset (Table 1), resulting in cutoffs of 2009-2016  
11 or 2017-2022.

## 12 **Results:**

13 A total of 25 pivotal phase III trials were included in the dataset. All were randomized  
14 controlled trials with the exception of the single-arm EVOLVE-MS-1 trial.<sup>26</sup> DMTs, regardless of  
15 treatment modality, showed a decline in ARR over the 30-year period demonstrating a general  
16 trend in increased efficacy (Figure 1). This was supported by a significant association between  
17 ARR less than 0.2 and more recent DMT approvals ( $p=0.020$ ). However, for SAE categorized at  
18 above and below 5%, we did not find a significant relationship with recently approved drugs  
19 ( $p=0.138$ ).

20 The other characteristics that we decided to investigate were related to mode of  
21 administration (oral vs. injection/infusion). Tolerability was assessed at a cutoff of 5% annual  
22 discontinuation probability, and there was no significant association with oral vs.  
23 injection/infusion ( $p=0.559$ ). Additionally, while there seemed to be a shift in developing more  
24 oral formulations as a higher proportion of recently approved DMTs were oral ( $n=6/11$ )  
25 compared to older approvals ( $n=2/8$ ), this was not statistically significant ( $p=0.352$ ). We did find  
26 recently approved DMTs had a positive significant association in the use of an active  
27 comparator vs. placebo ( $p=0.004$ ).

## 28 **Discussion:**

29 To our knowledge, this is the first study examining trends in efficacy, safety, and  
30 tolerability of MS DMTs inclusive of all currently approved therapies. Our findings support the  
31 notion that newer therapies are generally more effective. Should this trend continue MS will  
32 potentially become increasingly more manageable. Although no currently approved therapy is  
33 truly curative, the increasing potential to reduce probability of acute relapses, and by extension  
34 overall disease progression, offers hope for a future where patients with MS may experience a  
35 far lower average disease burden than historically.<sup>30</sup> The lack of a trend towards increasing  
36 safety is noteworthy; these therapies still undoubtedly have a positive risk/benefit profile for the  
37 vast majority of patients, however a greater focus on safety outcomes could be an area of focus  
38 in developing future therapies. Notably the trials referenced for our database focused  
39 specifically on RRMS, and indeed the majority of DMTs available are approved for management  
40 of RRMS and SPMS. Currently only ocrelizumab is FDA approved for PPMS and only  
41 mitoxantrone for PRMS. Other therapies may be used off-label for PPMS and PRMS, however  
42 their comparative efficacy and safety profiles are less clear in these contexts.<sup>31</sup> These subtypes

1 warrant further study to identify optimal medication therapy management and potential novel  
2 treatments.

3 Our findings on tolerability by route of administration were interesting given the  
4 widespread reputations of certain therapies included. Interferons, for instance, are notorious for  
5 significant dose limiting flu-like symptoms.<sup>32</sup> Injections and infusions also tend to have very high  
6 rates of injection site/infusion associated reactions. Notably the use of probability of  
7 discontinuation due to AEs may not fully elucidate tolerability of each drug as factors outside of  
8 AEs also weigh in. For example, injection anxiety<sup>33</sup> is an otherwise noted barrier to access for  
9 many individuals when choosing a prospective DMT; many patients may find frequent injections  
10 to be intolerable and avoid such medications altogether. With this in mind, the trend towards  
11 development and approval of comparably safe and effective oral therapies is altogether  
12 sensible, offering a more suitable option for many patients. Unfortunately many currently  
13 approved oral therapies also have a number of potentially dose-limiting AEs<sup>34</sup>, such as  
14 gastrointestinal upset, which is likely why our results indicated no significant difference in  
15 tolerability between oral therapies and alternatives when examining impact of AEs in isolation.  
16 Managing adverse effects of DMTs and increasing tolerability overall going forwards is an  
17 important consideration given the impact adherence to DMT regimens is noted to have on  
18 improving patient outcomes and reducing costs.<sup>35</sup>

19 The clear trend towards trial designs featuring active comparators in our dataset was to  
20 be expected given ethical considerations of withholding treatments that have increasingly  
21 become widely available, affordable, and proven effective in reducing burden of disease.  
22 Notably other studies have also acknowledged a shift towards implementation of active  
23 comparators in clinical trials.<sup>36</sup>

24 This study has several limitations. Generally, earlier trials were more limited in terms of  
25 reported outcomes, particularly in regard to MRI data and specific safety outcomes, limiting  
26 what could be included. Selected outcomes for this study were chosen on the basis that they  
27 were reported amongst all trials included over the respective date ranges chosen. However, we  
28 selected what we believed to be most RRMS such as ARR. Trial duration also varied, ranging  
29 from 48 to 104 weeks. We adjusted for this by using annualized rates. Another limitation was  
30 that earlier trials, particularly those conducted before widespread implementation of the  
31 McDonald Criteria as a standard for diagnosis, likely enrolled participants with a higher baseline  
32 disease burden when compared to contemporary trials. In addition, certain outcome measures  
33 such as measures of disability or severity of adverse effects have an inherent degree of  
34 subjectivity by nature, further complicated once again by differences in protocols between trials  
35 in defining such outcomes. The consolidation of IM injectables and IV infusions into one  
36 subgroup for analysis may also have implications as outcomes of interest may vary between  
37 these different routes of administration. However, for the purpose of comparing oral therapies to  
38 currently available alternatives, this grouping does provide clear insight.

### 39 **Conclusion:**

40 The number of FDA approved MS DMTs has gradually increased over the past 30 years.  
41 Data from phase III trials pivotal to each drug's approval supports trends in increasing efficacy  
42 but not safety over the period. Despite increasing adoption, there was no demonstrable

1 advantage of oral therapies over injections/infusions in terms of tolerability, and there has not  
2 been a significant shift towards oral therapy approvals. Studies have shifted towards inclusion of  
3 an active comparator rather than a placebo over time. Reported results are limited to patients  
4 with a diagnosis of RRMS; other subtypes of MS warrant further study.

1 **References:**


- 2 1. Leray E, Moreau T, Fromont A, et al. Epidemiology of multiple sclerosis. *Revue Neurologique*  
3 2016;172(1):3-13. doi: <https://doi.org/10.1016/j.neurol.2015.10.006>
- 4 2. Rejdak K, Jackson S, Giovannoni G. Multiple sclerosis: a practical overview for clinicians.  
5 *British Medical Bulletin* 2010;95(1):79-104. doi: 10.1093/bmb/ldq017
- 6 3. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of  
7 the McDonald criteria. *The Lancet Neurology* 2018;17(2):162-73. doi: 10.1016/s1474-  
8 4422(17)30470-2
- 9 4. De Angelis F, John NA, Brownlee WJ. Disease-modifying therapies for multiple sclerosis. *Bmj*  
10 2018;363:k4674. doi: 10.1136/bmj.k4674 [published Online First: 20181127]
- 11 5. Samjoo Imtiaz A, Worthington E, Drudge C, et al. Efficacy classification of modern therapies  
12 in multiple sclerosis. *Journal of Comparative Effectiveness Research* 2021;10(6):495-  
13 507. doi: 10.2217/ce-2020-0267
- 14 6. Calabresi PA, Kieseier BC, Arnold DL, et al. Pegylated interferon beta-1a for relapsing-  
15 remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. *The*  
16 *Lancet Neurology* 2014;13(7):657-65. doi: [https://doi.org/10.1016/S1474-  
17 4422\(14\)70068-7](https://doi.org/10.1016/S1474-4422(14)70068-7)
- 18 7. Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with  
19 relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised,  
20 placebo-controlled, phase 3 trial. *Lancet Neurol* 2014;13(6):545-56. doi: 10.1016/s1474-  
21 4422(14)70049-3 [published Online First: 20140328]
- 22 8. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing  
23 multiple sclerosis. *N Engl J Med* 2010;362(5):402-15. doi: 10.1056/NEJMoa0907839  
24 [published Online First: 20100120]
- 25 9. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line  
26 treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled  
27 phase 3 trial. *Lancet* 2012;380(9856):1819-28. doi: 10.1016/s0140-6736(12)61769-3  
28 [published Online First: 20121101]
- 29 10. Cohen JA, Comi G, Selmaj KW, et al. Safety and efficacy of ozanimod versus interferon  
30 beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-  
31 month, phase 3 trial. *The Lancet Neurology* 2019;18(11):1021-33. doi: 10.1016/S1474-  
32 4422(19)30238-8
- 33 11. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple  
34 sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. *The*  
35 *Lancet* 2012;380(9856):1829-39. doi: [https://doi.org/10.1016/S0140-6736\(12\)61768-1](https://doi.org/10.1016/S0140-6736(12)61768-1)
- 36 12. Comi G, Kappos L, Selmaj KW, et al. Safety and efficacy of ozanimod versus interferon  
37 beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum  
38 12-month, phase 3 trial. *Lancet Neurol* 2019;18(11):1009-20. doi: 10.1016/s1474-  
39 4422(19)30239-x [published Online First: 20190903]
- 40 13. Ebers GC. Randomised double-blind placebo-controlled study of interferon  $\beta$ -1a in  
41 relapsing/remitting multiple sclerosis. *The Lancet* 1998;352(9139):1498-504. doi:  
42 10.1016/S0140-6736(98)03334-0
- 43 14. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or  
44 glatiramer in multiple sclerosis. *N Engl J Med* 2012;367(12):1087-97. doi:  
45 10.1056/NEJMoa1206328
- 46 15. Giovannoni G, Comi G, Cook S, et al. A Placebo-Controlled Trial of Oral Cladribine for  
47 Relapsing Multiple Sclerosis. *New England Journal of Medicine* 2010;362(5):416-26. doi:  
48 10.1056/nejmoa0902533

- 1 16. Gold R, Kappos L, Arnold DL, et al. Placebo-Controlled Phase 3 Study of Oral BG-12 for  
2 Relapsing Multiple Sclerosis. *New England Journal of Medicine* 2012;367(12):1098-107.  
3 doi: 10.1056/NEJMoa1114287
- 4 17. Group TIMSS. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. *J*  
5 *Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial*  
6 1993;43(4):655-55. doi: 10.1212/wnl.43.4.655
- 7 18. Hartung H-P, Gonsette R, König N, et al. Mitoxantrone in progressive multiple sclerosis: a  
8 placebo-controlled, double-blind, randomised, multicentre trial. *The Lancet*  
9 2002;360(9350):2018-25. doi: [https://doi.org/10.1016/S0140-6736\(02\)12023-X](https://doi.org/10.1016/S0140-6736(02)12023-X)
- 10 19. Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus Teriflunomide in Multiple  
11 Sclerosis. *N Engl J Med* 2020;383(6):546-57. doi: 10.1056/NEJMoa1917246
- 12 20. Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing  
13 Multiple Sclerosis. *New England Journal of Medicine* 2017;376(3):221-34. doi:  
14 10.1056/nejmoa1601277
- 15 21. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease  
16 progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative  
17 Research Group (MSCRG). *Ann Neurol* 1996;39(3):285-94. doi:  
18 10.1002/ana.410390304
- 19 22. Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is  
20 well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and  
21 degree of disability. Copolymer 1 Multiple Sclerosis Study Group. *Neurology*  
22 1998;50(3):701-8. doi: 10.1212/wnl.50.3.701
- 23 23. Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive  
24 multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. *The Lancet*  
25 2018;391(10127):1263-73. doi: [https://doi.org/10.1016/S0140-6736\(18\)30475-6](https://doi.org/10.1016/S0140-6736(18)30475-6)
- 26 24. Kappos L, Fox RJ, Burcklen M, et al. Ponesimod Compared With Teriflunomide in Patients  
27 With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study.  
28 *JAMA Neurology* 2021;78(5):558. doi: 10.1001/jamaneurol.2021.0405
- 29 25. Kappos L, Radue E-W, O'Connor P, et al. A Placebo-Controlled Trial of Oral Fingolimod in  
30 Relapsing Multiple Sclerosis. *New England Journal of Medicine* 2010;362(5):387-401.  
31 doi: 10.1056/nejmoa0909494
- 32 26. Naismith RT, Wolinsky JS, Wundes A, et al. Diroximel fumarate (DRF) in patients with  
33 relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase  
34 3 EVOLVE-MS-1 study. *Multiple Sclerosis Journal* 2020;26(13):1729-39. doi:  
35 10.1177/1352458519881761
- 36 27. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for  
37 relapsing multiple sclerosis. *N Engl J Med* 2011;365(14):1293-303. doi:  
38 10.1056/NEJMoa1014656
- 39 28. Polman CH, O'Connor PW, Havrdova E, et al. A Randomized, Placebo-Controlled Trial of  
40 Natalizumab for Relapsing Multiple Sclerosis. *New England Journal of Medicine*  
41 2006;354(9):899-910. doi: 10.1056/nejmoa044397
- 42 29. Steinman L, Fox E, Hartung H-P, et al. Ublituximab versus Teriflunomide in Relapsing  
43 Multiple Sclerosis. *New England Journal of Medicine* 2022;387(8):704-14. doi:  
44 10.1056/nejmoa2201904
- 45 30. Torkildsen Ø, Myhr K-M, Bø L. Disease-modifying treatments for multiple sclerosis – a  
46 review of approved medications. *European Journal of Neurology* 2016;23(S1):18-27. doi:  
47 <https://doi.org/10.1111/ene.12883>
- 48 31. Chedid T, Moisset X, Clavelou P. Rationale for off-label treatments use in primary  
49 progressive multiple sclerosis: A review of the literature. *Revue Neurologique*  
50 2022;178(9):932-38. doi: <https://doi.org/10.1016/j.neurol.2022.02.461>



1 32. Munschauer FE, Kinkel RP. Managing side effects of interferon-beta in patients with  
2 relapsing-remitting multiple sclerosis. *Clinical Therapeutics* 1997;19(5):883-93. doi:  
3 [https://doi.org/10.1016/S0149-2918\(97\)80042-2](https://doi.org/10.1016/S0149-2918(97)80042-2)  
4 33. Turner AP, Williams RM, Sloan AP, et al. Injection anxiety remains a long-term barrier to  
5 medication adherence in multiple sclerosis. *Rehabil Psychol* 2009;54(1):116-21. doi:  
6 10.1037/a0014460  
7 34. Jivraj F, Kang S, Reddie S, et al. The Patient and Clinician Assessment of Gastrointestinal  
8 (GI) Related Adverse Events Associated with Oral Disease-Modifying Therapies in  
9 Multiple Sclerosis: A Qualitative Study. *Advances in Therapy* 2022;39(11):5072-86. doi:  
10 10.1007/s12325-022-02250-x  
11 35. Burks J, Marshall TS, Ye X. Adherence to disease-modifying therapies and its impact on  
12 relapse, health resource utilization, and costs among patients with multiple sclerosis.  
13 *ClinicoEconomics and Outcomes Research* 2017;9:251-60. doi:  
14 10.2147/CEOR.S130334  
15 36. Zhang Y, Salter A, Wallström E, et al. Evolution of clinical trials in multiple sclerosis.  
16 *Therapeutic Advances in Neurological Disorders* 2019;12:1756286419826547. doi:  
17 10.1177/1756286419826547  
18  
19

1 **Figure 1. Trends of annualize relapse rate by formulation type**



2  
3  
4  
5

1 **Table 1. Characteristics of multiple sclerosis disease modifying treatments**

2

Brand Name	Generic Name	Approval Date	Route	Comparator(s)	ARR <sup>†</sup>	DC <sup>‡</sup>	SAE <sup>‡</sup>
Betaseron	interferon beta-1b	July 23, 1993	injectable	placebo	0.84	-	-
Copaxone	glatiramer acetate	April 20, 1996	injectable	placebo	0.65	-	-
Avonex	interferon beta-1a	May 17, 1996	injectable	placebo	0.61	-	-
Novantrone	mitoxantrone	October 29, 2000	infusion	placebo	0.35	0.041	-
Rebif	interferon beta-1a	March 29, 2002	injectable	placebo	0.88	-	-
Tysabri	natalizumab	November 23, 2004	infusion	placebo	0.23	-	-
Gilenya	fingolimod	September 21, 2010	oral	both <sup>§</sup>	0.18	0.061	0.066
Aubagio	teriflunomide	September 12, 2012	oral	placebo	0.37	0.051	0.074
Tecfidera	dimethyl fumarate	March 27, 2013	oral	both <sup>¶</sup>	0.19	0.073	0.091
Plegridy	peginterferon beta-1a	August 15, 2014	injectable	placebo	0.25	0.054	0.118
Lemtrada	alemtuzumab	November 14, 2014	infusion	active*	0.22	0.010	0.100
Ocrevus	ocrelizumab	March 28, 2017	infusion	active	0.16	0.019	0.038
Mayzent	siponimod	March 26, 2019	oral	placebo	0.07	0.047	0.123
Mavenclad	cladribine	March 29, 2019	oral	placebo	0.14	-	0.046
Vumerity	diroximel fumarate	October 30, 2019	oral	single-arm**	0.16	0.034	0.041
Zeposia	ozanimod	March 25, 2020	oral	active*	0.17	0.015	0.033
Kesimpta	ofatumumab	August 20, 2020	injectable	active <sup>¶</sup>	0.10	0.036	0.057
Ponvory	ponesimod	March 18, 2021	oral	active	0.20	0.042	0.042
Briumvi	ublituximab-xiiy	December 28, 2022	infusion	active <sup>¶</sup>	0.08	0.022	0.060

† Weighted averages reported for drugs with multiple trials included

‡ Annual probabilities of serious adverse events and discontinuation due to adverse events as calculated from percentages reported in trials

§ Three trials included in dataset, two with placebo and one with active comparator

¶ Two trials included in dataset, one with placebo and one with active comparator

\* Two trials included in dataset, both with active comparator

\*\* Single-arm trial design, omitted from analysis

¶ Single publication included in dataset reporting results of two parallel studies, both included in dataset and both with active comparator

3  
4  
5  
6  
7  
8  
9  
10  
11